Enclomiphene

ID: enclomiphene

Aliases: enclomiphene citrate, Androxal

Type: compound

Route/form: oral

Status: investigational_or_compounded

Evidence level: human RCT

Best data tier: human controlled/review; exact-use indirect

Support scope: human, review/regulatory

Source types: human_rct, meta_analysis, review

Linked sources: 6

Broad outcomes: Hormones / fertility / sexual health, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• estrogen receptor antagonist in hypothalamic-pituitary axis
• LH/FSH upregulation

Optimization domains

• testosterone
• fertility
• endocrine
• pct discussions
• hpta support

Research basis

• Optimization angle: oral upstream HPTA stimulation when the goal is endogenous testosterone and fertility preservation rather than exogenous replacement.
• Human trials show enclomiphene can raise testosterone with LH/FSH stimulation and preserve sperm counts compared with testosterone gel in selected secondary-hypogonadism contexts.
• The clomiphene/enclomiphene RCT meta-analysis supports the broader SERM mechanism for male hypogonadism while still leaving bodybuilding-cycle recovery as a separate question.

Limits, risks, and missing evidence

• It is not a direct substitute for hCG during strong exogenous androgen suppression; if LH/FSH output is profoundly suppressed or the testes are not responding, upstream stimulation may not solve the problem.
• The strongest human data are hypogonadism/fertility-preservation trials, not PCT after high-dose AAS/SARM cycles.
• Visual symptoms, mood effects, estradiol shifts, clotting-risk questions, and compounded/product-quality variability still matter.

Risk flags

• prescription or compounded
• endocrine axis
• visual symptoms
• mood effects
• off label context

Linked papers, labels, and reviews

1. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men
   human_rct / pubmed_enclomiphene_phase3_2015
   Phase 3 studies compared with topical testosterone.
2. Enclomiphene citrate for the treatment of secondary male hypogonadism
   review / pubmed_enclomiphene_review_2016
   Review of enclomiphene in secondary hypogonadism.
3. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials
   meta_analysis / pubmed_enclomiphene_serm_hypogonadism_meta_2025
   RCT meta-analysis for clomiphene/enclomiphene in male hypogonadism; useful for HPTA-stimulation framing.
4. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone
   human_rct / pubmed_enclomiphene_phase2_sperm_2014
   Phase II trial comparing enclomiphene with topical testosterone; anchors endogenous testosterone plus sperm-preservation rationale.
5. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics
   human_rct / pubmed_enclomiphene_pkpd_2013
   Dose-ranging phase II pharmacodynamic/pharmacokinetic source for enclomiphene in secondary hypogonadism.
6. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel
   human_rct / pubmed_enclomiphene_vs_testosterone_gel_2013
   Human comparison with testosterone gel; central source for why enclomiphene is discussed differently from exogenous testosterone.